… cilostazol is limited owing to its poor aqueous solubility and oral bioavailability. Our aim was
to produce cilostazol … size distribution and stable polymorphic form to increase its dissolution …

… polymorph, Forms B and C are metastable, and Form C has a monoclinic crystal structure
[93]. Cilostazol … bioavailability, the therapeutic usage of cilostazol is limited. Therefore, several …

… cooling of cilostazol is believed to result in polymorphic transition… It may possibly reflect
polymorphic transition of the drug in … Polymorphism has been reported for cilostazol upon thermal …

… adopted to analyze the crystalline form of the raw materials and equilibrium solid phase
after experiments in each systems. The equilibrated cilostazol was recovered from equilibrium …

… has been able to generate any polymorphic form other than A for cilostazol, unlike for many
… govern the resulting crystalline form [81]. The chemical identity of cilostazol in every sample …

… maintained>90% of cilostazol in the solubilized form after 3 hours in non- … to prepare cilostazol
liquid oral dosage form using … Thermallyprepared polymorphic forms of cilostazol. J Pharm …

… Pure cilostazol presented peaks at 2θ angles of about 9.2, 12.8, 15.5, 18.6, 19.3, and 31.4
[… of form A of cilostazol [45]. However, the mixture of the three polymorphic forms [41,46] in the …

… In this study, we prepared the nanocrystal based on crystal polymorph of cilostazol (CLZ),
and found that the crystal polymorph affected the solubility, stability and bioavailability in the …

… 2 weeks after cilostazol treatment, the bending stiffness was significantly lower compared to
… significantly higher after cilostazol treatment. In conclusion, cilostazol delays fracture healing …